SARS-CoV-2 antigens & serological assay

Novel antigens could help detect, fight coronavirus

  • Custom antigens can be used to develop diagnostics and therapeutics for COVID-19
  • Antigens show specificity and selectivity for SARS-CoV-2 antibodies
  • Serologic assay shows high sensitivity and low background

 
Licensing Manager: Matt Boehm, Ph.D.
mboehm@unmc.edu or 402-559-2166
 

Description

Novel antigens could help detect, fight coronavirus

Researchers at the University of Nebraska Medical Center have identified SARS-CoV-2 protein antigens to help develop therapeutics and diagnostics for COVID-19.
 
The researchers have generated custom-designed viral protein sequences and expression constructs to serve as antigens in serological assays. Initial testing has shown the antigens can be used to differentiate between COVID-19 positive and COVID-19 negative patient samples. The proof-of-concept serological assay using the antigens demonstrated sensitivity and specificity for SARS-CoV-2 antibodies in serum and plasma.
 
The antigens can also be used in the design of therapeutics for the treatment of COVID-19 including antibody-based therapeutics as well as vaccines.
 
To discuss licensing opportunities related to diagnostic or therapeutic development related to these antigens, please contact Matt Boehm, Ph.D., at mboehm@unmc.edu or 402-559-2166.